Zacks Research Estimates Pfizer’s FY2025 Earnings (NYSE:PFE)

Pfizer Inc. (NYSE:PFE) – Research analysts at Zacks Research dropped their FY2025 earnings estimates for shares of Pfizer in a research report issued on Monday, October 21st. Zacks Research analyst K. Shah now anticipates that the biopharmaceutical company will post earnings of $2.79 per share for the year, down from their prior estimate of $2.81. The consensus estimate for Pfizer’s current full-year earnings is $2.66 per share. Zacks Research also issued estimates for Pfizer’s Q1 2026 earnings at $0.71 EPS, Q2 2026 earnings at $0.64 EPS, Q3 2026 earnings at $0.79 EPS and FY2026 earnings at $2.96 EPS.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. The firm had revenue of $13.28 billion during the quarter, compared to analysts’ expectations of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The company’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same quarter last year, the firm posted $0.67 earnings per share.

PFE has been the subject of several other research reports. Wells Fargo & Company boosted their price objective on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Thursday, October 3rd. Sanford C. Bernstein began coverage on shares of Pfizer in a report on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price for the company. UBS Group increased their price objective on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research report on Wednesday, July 31st. Finally, StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a research note on Wednesday, October 9th. Seven research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $33.91.

Pfizer Trading Down 0.3 %

NYSE PFE opened at $28.85 on Tuesday. Pfizer has a twelve month low of $25.20 and a twelve month high of $31.54. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. The stock’s 50-day simple moving average is $29.07 and its two-hundred day simple moving average is $28.48. The company has a market capitalization of $163.46 billion, a price-to-earnings ratio of -62.71, a PEG ratio of 1.02 and a beta of 0.67.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be paid a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 5.82%. The ex-dividend date is Friday, November 8th. Pfizer’s dividend payout ratio (DPR) is presently -365.21%.

Institutional Trading of Pfizer

Several large investors have recently added to or reduced their stakes in PFE. Tanager Wealth Management LLP purchased a new position in Pfizer during the third quarter valued at $233,000. International Assets Investment Management LLC bought a new position in shares of Pfizer during the 3rd quarter valued at approximately $146,481,000. Heartland Bank & Trust Co increased its holdings in Pfizer by 8.3% in the 3rd quarter. Heartland Bank & Trust Co now owns 23,068 shares of the biopharmaceutical company’s stock worth $668,000 after acquiring an additional 1,777 shares in the last quarter. McAdam LLC raised its stake in Pfizer by 13.9% during the 3rd quarter. McAdam LLC now owns 21,533 shares of the biopharmaceutical company’s stock worth $623,000 after acquiring an additional 2,628 shares during the period. Finally, Guidance Capital Inc. lifted its holdings in Pfizer by 2.1% during the third quarter. Guidance Capital Inc. now owns 34,886 shares of the biopharmaceutical company’s stock valued at $1,019,000 after purchasing an additional 706 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.